Novel trivalent inactivated vaccine for swine streptococcosis

A technology of Streptococcus suis and inactivated vaccine, applied in the direction of antibacterial drugs, bacterial antigen components, etc., can solve the problems of difficulty in prevention and treatment, and achieve the effect of strong immunogenicity, broad antigen spectrum and stable genetic performance

Active Publication Date: 2010-06-09
广东永顺生物制药股份有限公司
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, the pathogenic serogroups of Streptococcus suis that have occurred in various parts of our count

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] A new type of trivalent inactivated vaccine for streptococcus suis, consisting of inactivated, concentrated and qualified security inspection, treated with unique toxin removal technology C55138 antigen of Streptococcus equi subspecies zooepidemicus C55138, group D Coccus C55914 antigen and Lambert group E streptococcus C55949 antigen are prepared by mixing with adjuvant aluminum hydroxide glue, wherein the proportions of the three antigens are equal.

[0028] 1. Strains

[0029] a. Streptococcus equi subspecies zooepidemicus strain C55138 of Group C of Lambert: identified, kept and supplied by the China Veterinary Drug Control Institute.

[0030] b. Streptococcus strain C55914 of Group D of Lambert: identified, kept and supplied by China Veterinary Drug Control Institute.

[0031] c. Lambert Group E Streptococcus strain C55949: identified, kept and supplied by China Veterinary Drug Control Institute.

[0032] The above-mentioned Group C Streptococcus equi subspecies ...

Embodiment 2

[0063] Vaccine Efficacy Testing

[0064] With 15 healthy susceptible pigs, 2ml of the above-mentioned vaccine was injected intramuscularly, containing 1 dosage. After 21 days, the immune test pigs injected with the vaccine were divided into three groups, and the C group C55138, D group C55914 and Group E C55949 Streptococcus virulent strain challenge. 15 pigs in the control group were equally divided into three groups, and were challenged with the three virulent streptococcus strains of group C C55138, group D C55914 and group E C55949 respectively.

[0065] Streptococcus group C strain C55138: Select 5 immunized pigs, together with 5 control pigs with the same conditions, inject a lethal dose of virulent strain C55138 strain of group C, observe for 10 days, 4 / 5 of the immune pigs are protected, and the control pigs 4 / 5 or more death is qualified.

[0066] Streptococcus group D C55914 strain: Take 5 immunized pigs, together with 5 control pigs with the same conditions, inje...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel trivalent inactivated vaccine for swine streptococcosis, which is prepared by C55138 antigen of streptococcus equi subsp zooepidemicus of a lancefield group C, C55914 antigen of streptococcus of a lancefield group D and C55949 antigen of streptococcus of a lancefield group E through the steps of strain propagation, bacterium liquid culture, purity check, viable count, inactivation, detection of inactivation, precipitation and concentration, removal of toxins, mixing for hybridization, sterility test of vaccines, safety inspection of the vaccines, efficiency test and split charging. The novel trivalent inactivated vaccine of the swine streptococcosis prepared by the invention can prevent three types of swine streptococcosis caused by the streptococcus of thelancefield group C, the lancefield group D and the lancefield group E simultaneously and has wide application prospect.

Description

technical field [0001] The invention relates to the technical field of veterinary biological products, in particular to a trivalent inactivated vaccine for Streptococcus suis. Background technique [0002] Streptococcus suis is a common infectious disease, which is a general term for different symptom types caused by many different groups of Streptococcus. At present, there are reports of streptococcal disease in many countries and regions, and its prevalence is on the rise. The disease is mainly characterized by causing swine septicemia, suppurative lymphadenitis, meningitis, and arthritis. Under the action of some specific inducements, the mortality rate of affected pigs can reach about 80%, which seriously threatens the development of pig industry. [0003] Since the 1960s in China, streptococcal suis has occurred successively in Guangxi, Guangdong, Fujian, Hunan, Jiangxi, Anhui, Jiangsu, Sichuan and other places. Economic losses. There are many serogroups of Streptoco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/116A61K39/09A61P31/04
Inventor 以体强林旭埜张毓金游启有杨球郭沈涛王少英
Owner 广东永顺生物制药股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap